1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Infliximab Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 199 Wenhai North Road
          HEDA, Hangzhou - Zhejiang Province - CHINA  310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Amorphous powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
</tbody>
</table>

Not a hazardous substance or mixture.

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Not classified based on available information.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Infliximab Formulation

Version 1.14  Revision Date: 09/13/2019  SDS Number: 19267-00015  Date of last issue: 2019/04/24
Date of first issue: 2014/10/07

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&gt;= 70 -&lt; 90</td>
</tr>
<tr>
<td>Infliximab</td>
<td>170277-31-3</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: No special precautions are necessary for first aid responders.

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.
6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents
8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Infliximab</td>
<td>170277-31-3</td>
<td>TWA</td>
<td>150 µg/m³</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures
- Ensure adequate ventilation, especially in confined areas.
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type

Eye/face protection
- Wear the following personal protective equipment:
  - Safety goggles

Skin and body protection
- Skin should be washed after contact.

Hand protection
- Chemical-resistant gloves

Material
- For prolonged or repeated contact use protective gloves.
  - Wash hands before breaks and at the end of workday.

Hygiene measures
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
  - When using do not eat, drink or smoke.
  - Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Amorphous powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>7.2</td>
</tr>
</tbody>
</table>
## 5. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling</td>
<td>No data available</td>
</tr>
<tr>
<td>range</td>
<td></td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Lower explosion limit / Lower</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>1 g/cm³</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

## 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
</tbody>
</table>
Infliximab Formulation

Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Sucrose:
Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Infliximab:
Remarks: No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Infliximab:
Remarks: No data available

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:
Sucrose:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Infliximab:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Method: OECD Test Guideline 474
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Infliximab:
Effects on fertility: Test Type: Fertility
Species: Mouse
Application Route: Intravenous injection
Fertility: NOAEL: 40 mg/kg body weight
Remarks: Based on data from similar materials

Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse, female
Application Route: Intravenous injection
Duration of Single Treatment: 6 - 12 d
General Toxicity Maternal: NOAEL: 40 mg/kg body weight
Teratogenicity: NOAEL F1: 40 mg/kg body weight
Developmental Toxicity: NOAEL F1: 40
Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.
### Repeated dose toxicity

**Components:**

**Infliximab:**
- **Species:** Mouse
- **NOAEL:** 40 mg/kg
- **Application Route:** Intravenous
- **Exposure time:** 6 Months
- **Number of exposures:** daily

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

**Components:**

**Infliximab:**
- **Inhalation:** Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, Fatigue, Headache, Back pain

### 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

**Components:**

**Infliximab:**

**Ecotoxicology Assessment**
- **Acute aquatic toxicity:** No data available
- **Chronic aquatic toxicity:** No data available

#### Persistence and degradability

No data available

#### Bioaccumulative potential

**Components:**

**Sucrose:**
- **Partition coefficient: n-octanol/water:** Pow: < 1

**Mobility in soil**

No data available

**Other adverse effects**

No data available
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Infliximab Formulation

Version 1.14  Revision Date: 09/13/2019  SDS Number: 19267-00015  Date of last issue: 2019/04/24
Date of first issue: 2014/10/07

13. DISPOSAL CONSIDERATIONS

Disposal methods
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
  If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
- AICS: not determined
- DSL: not determined
- IECSC: not determined

16. OTHER INFORMATION

Further information
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Infliximab Formulation

Version 1.14  Revision Date: 09/13/2019  SDS Number: 19267-00015  Date of last issue: 2019/04/24  Date of first issue: 2014/10/07

Date format: yyyy/mm/dd

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA: 8-hour, time-weighted average

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN